Rifaximin in the treatment of recurrent Clostridium difficile infection

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 1, 2013, Pages 122-128

  Mattila, E ^a   Arkkila, P ^a   Mattila, P S ^a   Tarkka, E ^a   Tissari, P ^a   Anttila, V J ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; METRONIDAZOLE; RIFACOL; RIFAMPICIN; RIFAXIMIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM COLONY; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLOSTRIDIUM DIFFICILE INFECTION; CONCENTRATION RESPONSE; CONVALESCENCE; DNA DETERMINATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG THERAPY, COMBINATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RIFAMYCINS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 84870602848     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12111     Document Type: Article

References (45)

1. O'Donoghue C, Kyne L,. Update on Clostridium difficile infection. Curr Opin Gastroenterol 2011; 27: 38-47.
2. Lo Vecchio A, Zacur GM,. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012; 28: 1-9.
3. Drekonja DM, Butler M, MacDonald R, et al,. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med 2011; 155: 839-47.
4. Cocanour CS,. Best strategies in recurrent or persistent Clostridium difficile infection. Surg Infect 2011; 12: 235-9.
5. Landy J, Al-Hassi HO, McLaughlin SD, et al,. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011; 34: 409-15.
6. Mattila E, Uusitalo-Seppala R, Wuorela M, et al,. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012; 142: 490-6.
7. Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA,. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012; 35: 865-75.
8. Mattila E, Anttila VJ, Broas M, et al,. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis 2008; 40: 702-8.
9. Lowy I, Molrine DC, Leav BA, et al,. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197-205.
10. Shah D, Dang MD, Hasbun R, et al,. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010; 8: 555-64.
11. Louie TJ, Miller MA, Mullane KM, et al,. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
12. Cornely OA, Crook DW, Esposito R, et al,. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281-9.
13. DuPont HL, Jiang ZD, Okhuysen PC, et al,. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005; 142: 805-12.
14. Layer P, Andresen V,. Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea. Aliment Pharmacol Ther 2010; 31: 1155-64.
15. Rivkin A, Gim S,. Rifaximin: new therapeutic indication and future directions. Clin Ther 2011; 33: 812-27.
16. Prantera C, Lochs H, Grimaldi M, et al,. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142: e4.
17. Berman AL,. Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2007; 41: 932-3.
18. Garey KW, Salazar M, Shah D, Rodrigue R, DuPont HL,. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 2008; 42: 827-35.
19. Garey KW, Ghantoji SS, Shah DN, et al,. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011; 66: 2850-5.
20. Antikainen J, Pasanen T, Mero S, et al,. Detection of virulence genes of Clostridium difficile by multiplex PCR. APMIS 2009; 117: 607-13.
21. Basu PP, Dinani A, Rayapudi K, et al,. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol 2011; 3: 221-5.
22. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN,. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44: 846-8.
23. Johnson S, Schriever C, Patel U, Patel T, Hecht DW, Gerding DN,. Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009; 15: 290-1.
24. Bauer MP, Kuijper EJ, van Dissel JT,. European Society of Clinical Microbiology and Infectious D. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067-79.
25. Cohen SH, Gerding DN, Johnson S, et al,. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
26. Gujja D, Friedenberg FK,. Predictors of serious complications due to Clostridium difficile infection. Aliment Pharmacol Ther 2009; 29: 635-42.
27. Eyre DW, Walker AS, Wyllie D, et al,. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012; 55 (Suppl. 2): S77-87.
28. Dalton BR, Lye-Maccannell T, Henderson EA, Maccannell DR, Louie TJ,. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment Pharmacol Ther 2009; 29: 626-34.
29. Bavishi C, Dupont HL,. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34: 1269-81.
30. Khanna S, Pardi DS, Aronson SL, Kammer PP, Baddour LM,. Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol Ther 2012; 35: 613-8.
31. Ananthakrishnan AN, Guzman-Perez R, Gainer V, et al,. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 789-95.
32. O'Connor JR, Galang MA, Sambol SP, et al,. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008; 52: 2813-7.
33. Miller MA, Blanchette R, Spigaglia P, Barbanti F, Mastrantonio P,. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol 2011; 49: 4319-21.
34. Huhulescu S, Sagel U, Fiedler A, et al,. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile. J Med Microbiol 2011; 60: 1206-12.
35. Spigaglia P, Barbanti F, Mastrantonio P,; European Study Group on Clostridium d. Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother 2011; 66: 2227-34.
36. Curry SR, Marsh JW, Shutt KA, et al,. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009; 48: 425-9.
37. Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H,. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000; 44: 2205-6.
38. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN,. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51: 2716-9.
39. Citron DM, Babakhani F, Goldstein EJ, et al,. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe 2009; 15: 234-6.
40. Huang H, Weintraub A, Fang H, Wu S, Zhang Y, Nord CE,. Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains. Anaerobe 2010; 16: 633-5.
41. Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN,. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother 2011; 55: 5194-9.
42. Warny M, Pepin J, Fang A, et al,. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-84.
43. Walk ST, Micic D, Jain R, et al,. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 2012 55 1661-8.
44. Carman RJ, Boone JH, Grover H, Wickham NK, Chen L,. In vivo selection of rifamycin resistant Clostridium difficile during rifaximin therapy. Antimicrob Agents Ch 2012; 56 6019-20.
45. Jiang ZD, DuPont HL, La Rocco M, Garey KW,. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol 2010; 63: 355-8.